MedPath

12-hour Versus 24-hour Magnesium Sulfate Regimen for the Management of Severe Preeclampsia

Phase 3
Not yet recruiting
Conditions
Pregnancy and Childbirth
Registration Number
PACTR202304555642144
Lead Sponsor
Samah Mohammed Ahmed Hussein
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
320
Inclusion Criteria

Pregnant women with a viable fetus.
Age from 18 to 44 years old.
Admitted to the hospital's obstetrics unit for inpatient care.
Diagnosed with severe preeclampsia.
Severe preeclampsia is defined as blood pressure equal to or greater than 160/110 mm Hg at a single reading with proteinuria of 2+ on dipstick or 24-hour urinary protein of more than 5g, oliguria urine output of less than less than 30 mL/hour, cerebral or visual disturbances, renal failure as persistent oliguria despite of using of intravenous fluid and furosemide challenge with deranged serum electrolytes, rising creatinine greater than 1.5 mg/L, and urea greater than 45 mg/ dL”, pulmonary edema or cyanosis, epigastric or right upper quadrant pain, impaired liver function, thrombocytopenia, or fetal growth restriction.

Exclusion Criteria

Women with any condition considered as a contraindication for MgSo4 therapy, like:
Drug hypersensitivity
Myasthenia gravis
Anuria
Oliguria
Prior intake of any other anticonvulsant
History of epilepsy
Women with diabetes mellitus.
Women with HELP syndrome (hemolysis, elevated liver enzymes, and low platelets).

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.